Illumina prefers to spin off Grail into an independent business rather than selling the cancer diagnostics company, according ...

Vertex said it's making strong progress bringing its CRISPR Therapeutics-partnered gene therapy to patients after a landmark approval for sickle cell disease in December. Chief operating officer ...

Senate HELP committee ranking member Bill Cassidy (R-LA) is calling on the Biden administration to do a better job of ...

The University of Pennsylvania’s pioneering cell therapy physician Carl June shared new data Monday that showed the risk of ...

In the first of what's expected to be a series of REMS-related advice for the industry, the FDA on Monday unveiled new draft ...

Gossamer Bio has lined up a partner to foot the development and commercialization bill for its make-or-break late-stage drug, ...

Eccogene, a Boston and Shanghai biotech working on an oral GLP-1 candidate with AstraZeneca, is considering an initial public ...

GlycoMimetics’ stock $GLYC tanked over 60% in premarket trading Monday morning after the biotech announced a Phase 3 trial ...

UK pharma giant AstraZeneca on Monday unveiled another $140 million equity investment in cell and gene therapy partner ...

Pfizer has tapped Wall Street analyst Andrew Baum to be its new chief strategy and innovation officer, where he'll head up ...

Plus, news about EyePoint, Lyra Therapeutics and Plus Therapeutics: For global health, $300 million: The Bill & Melinda Gates Foundation, the Novo Nordisk Foundation and Wellcome are each pitching in ...

A new biotech is coming out of stealth with $16 million to develop cell therapies for solid cancers — an area where scientists have had limited success. OverT Bio (pronounced ...